

**BIOTEQUE CORPORATION AND SUBSIDIARIES****Consolidated Financial Statements****With Independent Auditors' Review Report  
For the Three Months Ended March 31, 2019 and 2018**

Address: 5F.-6, No.23, Sec.1. Chang-An E. Rd., Taipei City 104, Taiwan (R.O.C.)  
Telephone: +886-2-2571-0269

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

## Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Consolidated Balance Sheets	4
5. Consolidated Statements of Comprehensive Income	5
6. Consolidated Statements of Changes in Equity	6
7. Consolidated Statements of Cash Flows	7
8. Notes to the Consolidated Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the consolidated financial statements	8
(3) New standards, amendments and interpretations adopted	8~11
(4) Summary of significant accounting policies	11~14
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	14
(6) Explanation of significant accounts	14~35
(7) Related-parties transactions	35
(8) Pledged assets	35
(9) Commitments and contingencies	36
(10) Losses Due to Major Disasters	36
(11) Subsequent Events	36
(12) Other	36
(13) Other disclosures	
(a) Information on significant transactions	37~39
(b) Information on investees	39
(c) Information on investment in mainland China	39
(14) Segment information	40



安侯建業聯合會計師事務所  
KPMG

台北市11049信義路5段7號68樓(台北101大樓)  
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,  
Xinyi Road, Taipei City 11049, Taiwan (R.O.C.)

Telephone 電話 + 886 (2) 8101 6666  
Fax 傳真 + 886 (2) 8101 6667  
Internet 網址 kpmg.com/tw

## Independent Auditors' Review Report

To the Board of Directors of Bioteque Corporation:

### Introduction

We have reviewed the accompanying consolidated balance sheets of Bioteque Corporation (the “Company”) and its subsidiaries (together referred to as the “Group”) as of March 31, 2019 and 2018, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2019 and 2018, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

### Scope of Review

We conducted our reviews in accordance with Statement of Auditing Standard 65, “Review of Financial Information Performed by the Independent Auditor of the Entity”. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the generally accepted auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Bioteque Corporation and its subsidiaries as of March 31, 2019 and 2018, and of its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2019 and 2018 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.



The engagement partners on the reviews resulting in this independent auditors' review report are Ya-Ling Chen and Yen-Ta Su.

KPMG

Taipei, Taiwan (Republic of China)

May 7, 2019

#### **Notes to Readers**

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)  
**Reviewed only, not audited in accordance with the generally accepted auditing standards as of March 31, 2019 and 2018**

**BIOTEQUE CORPORATION AND SUBSIDIARIES**

Consolidated Balance Sheets

March 31, 2019, December 31 and March 31, 2018

(expressed in Thousands of New Taiwan Dollars)

	March 31, 2019		December 31, 2018		March 31, 2018	
	Amount	%	Amount	%	Amount	%
<b>Assets</b>						
<b>Current assets:</b>						
1100 Cash and cash equivalents (note 6(a))	\$ 1,065,930	36	926,601	33	1,008,040	37
1110 Current financial assets at fair value through profit or loss (note 6(b))	177,223	6	176,325	6	173,004	6
1150 Notes receivable, net (notes 6(d) and (n))	70,595	3	71,638	3	72,370	2
1170 Accounts receivable, net (notes 6(d) and (n))	204,898	7	211,038	8	209,299	8
130X Inventories (note 6(e))	279,312	10	281,734	10	208,913	8
1476 Other current financial assets (note 8)	1,613	-	1,943	-	1,852	-
1479 Other current assets	28,155	1	21,715	1	19,409	1
<b>Total current assets</b>	<u>1,827,726</u>	<u>63</u>	<u>1,690,994</u>	<u>61</u>	<u>1,692,887</u>	<u>62</u>
<b>Non-current assets:</b>						
1517 Non-current financial assets at fair value through other comprehensive income (note 6(c))	222	-	237	-	307	-
1600 Property, plant and equipment (notes 6(f) and 8)	940,904	32	944,734	34	938,581	35
1755 Right-of-use assets (note 6(g))	69,811	2	-	-	-	-
1840 Deferred tax assets	2,657	-	2,657	-	3,066	-
1915 Prepayments for business facilities (note 9)	75,599	3	77,393	3	26,309	1
1980 Other non-current financial assets	1,999	-	1,972	-	1,751	-
1995 Other non-current assets	3,969	-	53,555	2	53,724	2
<b>Total non-current assets</b>	<u>1,095,161</u>	<u>37</u>	<u>1,080,548</u>	<u>39</u>	<u>1,023,738</u>	<u>38</u>
<b>Liabilities and Equity</b>						
<b>Current liabilities:</b>						
Short-term borrowings (notes 6(h) and 8)	\$ -	-	25,000	1	80,000	3
Current contract liabilities (notes 6(n))	51,017	2	33,923	1	23,106	1
Notes payable	39,223	1	37,807	2	38,729	1
Accounts payable	78,507	3	75,256	3	69,122	3
Other payables (notes 6(o))	106,466	4	104,116	4	92,409	3
Payable on machinery and equipment	3,347	-	5,941	-	2,294	-
Current tax liabilities	89,388	3	61,746	2	68,215	3
Current lease liabilities (notes 6(i) and 6(u))	4,877	-	-	-	-	-
Long-term liabilities, current portion (notes 6(h) and 6(u))	28,243	1	35,840	1	44,878	2
Other current liabilities	8,916	-	6,019	-	13,232	-
<b>Total current liabilities</b>	<u>409,984</u>	<u>14</u>	<u>385,648</u>	<u>14</u>	<u>431,985</u>	<u>16</u>
<b>Non-Current liabilities:</b>						
Long-term borrowings (notes 6(b), 6(t) and 9)	5,135	-	10,240	-	31,536	1
Deferred tax liabilities	51,521	2	51,521	2	38,448	1
Non-current lease liabilities (notes 6(i) and 6(u))	14,253	1	-	-	-	-
Other non-current liabilities	8	-	8	-	7	-
Net defined benefit liability, non-current	10,227	-	10,098	1	7,339	-
<b>Total non-current liabilities</b>	<u>81,144</u>	<u>3</u>	<u>71,867</u>	<u>3</u>	<u>77,330</u>	<u>2</u>
<b>Total liabilities</b>	<u>491,128</u>	<u>17</u>	<u>457,515</u>	<u>17</u>	<u>509,315</u>	<u>18</u>
<b>Equity attributable to owners of parent (note 6(i)):</b>						
Ordinary shares	692,983	24	692,983	25	692,983	26
Capital surplus	315,168	11	315,168	11	315,168	12
Retained earnings:						
Legal reserve	283,404	10	283,404	10	253,010	9
Special reserve	6,459	-	6,459	-	-	-
Unappropriated retained earnings	1,121,066	38	1,005,069	37	964,945	36
Other equity interest:	1,410,929	48	1,294,932	47	1,217,955	45
Exchange differences on translation of foreign financial statements	14,008	-	12,259	-	(17,551)	(1)
Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	(1,329)	-	(1,315)	-	(1,245)	-
<b>Total equity</b>	<u>2,431,759</u>	<u>83</u>	<u>2,314,027</u>	<u>83</u>	<u>2,207,310</u>	<u>82</u>
<b>Total liabilities and equity</b>	<u>\$ 2,922,887</u>	<u>100</u>	<u>\$ 2,771,542</u>	<u>100</u>	<u>\$ 2,716,625</u>	<u>100</u>

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)  
Reviewed only, not audited in accordance with generally accepted auditing standards

**BIOTEQUE CORPORATION AND SUBSIDIARIES**

**Consolidated Statements of Comprehensive Income**

**For the three months ended March 31, 2019 and 2018**

(expressed in Thousands of New Taiwan Dollars , Except for Earnings Per Common Share)

		<u>For the three months ended March 31</u>			
		<u>2019</u>		<u>2018</u>	
		<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>
4000	Operating revenue (notes 6(n))	\$ 440,714	100	375,908	100
5000	Operating costs (notes 6(e), (f), (g), (j) and 12)	<u>251,009</u>	<u>57</u>	<u>216,816</u>	<u>58</u>
	Gross profit from operations	<u>189,705</u>	<u>43</u>	<u>159,092</u>	<u>42</u>
6000	Operating expenses (notes 6(f), (g), (j), (o), 7 and 12):				
6100	Selling expenses	21,476	5	15,431	4
6200	Administrative expenses	23,242	5	21,572	6
6300	Research and development expenses	<u>9,044</u>	<u>2</u>	<u>8,691</u>	<u>2</u>
	Total operating expenses	<u>53,762</u>	<u>12</u>	<u>45,694</u>	<u>12</u>
6900	Net operating income	<u>135,943</u>	<u>31</u>	<u>113,398</u>	<u>30</u>
7000	Non-operating income and expenses (note 6(p)):				
7010	Other income	3,450	-	3,095	1
7020	Other gains and losses	4,884	1	(10,214)	(3)
7050	Finance costs	<u>(475)</u>	<u>-</u>	<u>(785)</u>	<u>-</u>
	Total non-operating income and expenses	<u>7,859</u>	<u>1</u>	<u>(7,904)</u>	<u>(2)</u>
7900	Profit before tax	143,802	32	105,494	28
7951	Less: Tax expenses (note 6(k))	<u>27,805</u>	<u>6</u>	<u>22,623</u>	<u>6</u>
	Profit	<u>115,997</u>	<u>26</u>	<u>82,871</u>	<u>22</u>
8300	Other comprehensive income (loss) (note 6(l)):				
8310	Components of other comprehensive income that will not be reclassified to profit or loss:				
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	(14)	-	(21)	-
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
	Total components of other comprehensive income (loss) that will not be reclassified to profit or loss	<u>(14)</u>	<u>-</u>	<u>(21)</u>	<u>-</u>
8360	Components of other comprehensive income (loss) that will be reclassified to profit or loss:				
8361	Exchange differences on translation	1,749	1	(12,316)	(3)
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
	Total components of other comprehensive income (loss) that will be reclassified to profit or loss	<u>1,749</u>	<u>1</u>	<u>(12,316)</u>	<u>(3)</u>
8300	Other comprehensive income (loss), net	<u>1,735</u>	<u>1</u>	<u>(12,337)</u>	<u>(3)</u>
	Comprehensive income	<u>\$ 117,732</u>	<u>27</u>	<u>70,534</u>	<u>19</u>
	Profit, attributable to:				
	Profit, attributable to owners of parent	<u>\$ 115,997</u>	<u>26</u>	<u>82,871</u>	<u>22</u>
	Comprehensive income, attributable to:				
	Comprehensive income, attributable to owners of parent	<u>\$ 117,732</u>	<u>27</u>	<u>70,534</u>	<u>19</u>
9750	Basic earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)	<u>\$ 1.67</u>		<u>1.20</u>	
9850	Diluted earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)	<u>\$ 1.67</u>		<u>1.19</u>	

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)  
**Reviewed only, not audited in accordance with generally accepted auditing standards**

**BIOTEQUE CORPORATION AND SUBSIDIARIES**

**Consolidated Statements of Changes in Equity**

**For the three months ended March 31, 2019 and 2018**

(expressed in Thousands of New Taiwan Dollars)

	Attributable to owners of parent							Total equity
	Retained earnings			Other equity interest		Unrealized gains		
Ordinary shares	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings	Exchange differences on translation of foreign financial statements	(losses) from financial assets measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	
\$ 692,983	315,168	253,010	-	882,074	(5,235)	-	(1,224)	2,136,776
-	-	-	-	-	-	(1,224)	1,224	-
692,983	315,168	253,010	-	882,074	(5,235)	(1,224)	-	2,136,776
-	-	-	-	82,871	-	-	-	82,871
-	-	-	-	-	(12,316)	(21)	-	(12,337)
-	-	-	-	82,871	(12,316)	(21)	-	70,534
\$ 692,983	315,168	253,010	-	964,945	(17,551)	(1,245)	-	2,207,310
\$ 692,983	315,168	283,404	6,459	1,005,069	12,259	(1,315)	-	2,314,027
-	-	-	-	115,997	-	-	-	115,997
-	-	-	-	-	1,749	(14)	-	1,735
-	-	-	-	115,997	1,749	(14)	-	117,732
\$ 692,983	315,168	283,404	6,459	1,121,066	14,008	(1,329)	-	2,431,759

**Balance at January 1, 2018**

Effects of retrospective application

Balance at January 1, 2018 after adjustments

Net income for the three months ended March 31, 2018

Other comprehensive income for the three months ended March 31, 2018

Total comprehensive income for the three months ended March 31, 2018

**Balance at March 31, 2018**

**Balance at January 1, 2019**

Net income for the three months ended March 31, 2019

Other comprehensive income for the three months ended March 31, 2019

Total comprehensive income for the three months ended March 31, 2019

**Balance at March 31, 2019**

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)  
Reviewed only, not audited in accordance with generally accepted auditing standards

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Consolidated Statements of Cash Flows**  
**For the three months ended March 31, 2019 and 2018**  
**(expressed in Thousands of New Taiwan Dollars)**

	For the three months ended March 31	
	2019	2018
<b>Cash flows generated from (used in) operating activities:</b>		
<b>Profit before tax</b>	\$ 143,802	105,494
<b>Adjustments:</b>		
<b>Adjustments to reconcile profit (loss):</b>		
Depreciation expense	22,751	19,689
Amortization expense	691	1,026
Net (gain) loss on financial assets at fair value through profit or loss	(613)	1
Interest expense	475	785
Interest income	(1,860)	(1,140)
Loss on disposal of property, plant and equipment	-	26
<b>Total adjustments to reconcile profit</b>	<u>21,444</u>	<u>20,387</u>
<b>Changes in operating assets:</b>		
Notes receivable	1,043	2,353
Accounts receivable	6,140	(16,470)
Inventories	2,422	(11,321)
Other current assets	(6,928)	3,426
Other financial assets	330	(417)
<b>Total changes in operating assets</b>	<u>3,007</u>	<u>(22,429)</u>
<b>Changes in operating liabilities:</b>		
Current contract liabilities	17,094	23,106
Notes payable	1,416	(4,468)
Accounts payable	3,251	15,317
Other payable	2,322	(4,809)
Net defined benefit liability	129	48
Other current liabilities	2,897	(13,968)
<b>Total changes in operating liabilities</b>	<u>27,109</u>	<u>15,226</u>
<b>Total changes in operating assets and liabilities</b>	<u>30,116</u>	<u>(7,203)</u>
<b>Total adjustments</b>	<u>51,560</u>	<u>13,184</u>
Cash inflow generated from operations	195,362	118,678
Interest received	1,618	911
Income taxes paid	(162)	(464)
<b>Net cash flows generated from operating activities</b>	<u>196,818</u>	<u>119,125</u>
<b>Cash flows generated from (used in) investing activities:</b>		
Acquisition of financial assets at fair value through profit or loss	(30,607)	(28,457)
Proceeds from disposal of financial assets at fair value through profit or loss	30,412	28,345
Acquisition of property, plant and equipment	(10,439)	(6,707)
Proceeds from disposal of property, plant and equipment	-	104
(Increase) decrease in other non-current financial assets	(27)	29
Increase in other non-current assets	(1,103)	(76)
Increase in prepayments for business facilities	(6,567)	(5,664)
Decrease in payables on machinery and equipment	(2,594)	(7,184)
<b>Net cash flows used in investing activities</b>	<u>(20,925)</u>	<u>(19,610)</u>
<b>Cash flows generated from (used in) financing activities:</b>		
Decrease in short-term loans	(25,000)	-
Repayments of long-term borrowings	(12,844)	(3,663)
Decrease in guarantee deposits	-	(1)
Payment of lease liabilities	(1,224)	-
Interest paid	(447)	(883)
<b>Net cash flows used in financing activities</b>	<u>(39,515)</u>	<u>(4,547)</u>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	<u>2,951</u>	<u>(3,782)</u>
<b>Net increase in cash and cash equivalents</b>	<u>139,329</u>	<u>91,186</u>
<b>Cash and cash equivalents at beginning of period</b>	<u>926,601</u>	<u>916,854</u>
<b>Cash and cash equivalents at end of period</b>	<u>\$ 1,065,930</u>	<u>1,008,040</u>

See accompanying notes to consolidated financial statements.



(English Translation of Consolidated Financial Statements Originally Issued in Chinese)  
Reviewed only, not audited in accordance with generally accepted auditing standards as of March 31, 2019 and 2018

## BIOTEQUE CORPORATION AND SUBSIDIARIES

### Notes to the Consolidated Financial Statements

March 31, 2019 and 2018

(Expressed in Thousands of New Taiwan Dollars except for Earning Per Share Information  
and Unless Otherwise Specified)

#### (1) Company history

Bioteque Corporation (“the Company”) was incorporation in November, 1991 in accordance with The Company Act and the other related laws and regulations.

The Company’s stock was listed on Taipei Exchange on March 4, 2002.

The business operation of the Company and its subsidiaries (together referred to as “the Group”) are as follows:

- (a) Manufacturing, trading and selling of the medical equipment and instruments.
- (b) Reinvestment and monopoly investment in securities business.

Please refer to note 14 for the related information.

#### (2) Approval date and procedures of the consolidated financial statements:

The consolidated financial statements for the three months ended March 31, 2019 and 2018 were authorized for issuance by the board of directors on May 7, 2019.

#### (3) New standards, amendments and interpretations adopted:

- (a) The impact of the International Financial Reporting Standards (“IFRSs”) endorsed by the Financial Supervisory Commission, R.O.C. (“FSC”) which have already been adopted.

The following new standards, interpretations and amendments have been endorsed by the FSC and are effective for annual periods beginning on or after January 1, 2019.

New, Revised or Amended Standards and Interpretations	Effective date per IASB
IFRS 16 “Leases”	January 1, 2019
IFRIC 23 “Uncertainty over Income Tax Treatments”	January 1, 2019
Amendments to IFRS 9 “Prepayment features with negative compensation”	January 1, 2019
Amendments to IAS 19 “Plan Amendment, Curtailment or Settlement”	January 1, 2019
Amendments to IAS 28 “Long-term interests in associates and joint ventures”	January 1, 2019
Annual Improvements to IFRS Standards 2015–2017 Cycle	January 1, 2019

(Continued)

## **BIOTEQUE CORPORATION AND SUBSIDIARIES**

### **Notes to the Consolidated Financial Statements**

Except for the following items, the Group believes that the adoption of the above IFRSs would not have any material impact on its consolidated financial statements. The extent and impact of signification changes are as follows:

(i) IFRS 16“Leases”

IFRS 16 replaces the existing leases guidance, including IAS 17 Leases, IFRIC 4 Determining whether an Arrangement contains a Lease, SIC-15 Operating Leases – Incentives and SIC-27 Evaluating the Substance of Transactions Involving the Legal Form of a Lease.

The Group applied IFRS 16 using the modified retrospective approach. The details of the changes in accounting policies are disclosed below:

1) Definition of a lease

Previously, the Group determined at contract inception whether an arrangement is or contains a lease under IFRIC 4. Under IFRS 16, the Group assesses whether a contract is or contains a lease based on the definition of a lease, as explained in Note 4(c).

On transition to IFRS 16, the Group elected to apply the practical expedient to grandfather the assessment of which transactions are leases. The Group applied IFRS 16 only to contracts that were previously identified as leases. Contracts that were not identified as leases under IAS 17 and IFRIC 4 were not reassessed for whether there is a lease. Therefore, the definition of a lease under IFRS 16 was applied only to contracts entered into or changed on or after January 1, 2019.

2) As a lessee

As a lessee, the Group previously classified leases as operating or finance leases based on its assessment of whether the lease transferred significantly all of the risks and rewards incidental to ownership of the underlying asset to the Group. Under IFRS 16, the Group recognizes right-of-use assets and lease liabilities for most leases – i.e. these leases are on-balance sheet.

- Leases classified as operating leases under IAS 17

At transition, lease liabilities were measured at the present value of the remaining lease payments, discounted at the Group’s incremental borrowing rate as at January 1, 2019. Right-of-use assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments – the Group applied this approach to all other lease.

In addition, the Group used the following practical expedients when applying IFRS 16 to leases.

- Applied a single discount rate to a portfolio of leases with similar characteristics.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

- Adjusted the right-of-use assets by the amount of IAS 37 onerous contract provision immediately before the date of initial application, as an alternative to an impairment review.
- Applied the exemption not to recognize right-of-use assets and liabilities for leases with less than 12 months of lease term.
- Excluded initial direct costs from measuring the right-of-use asset at the date of initial application.
- Used hindsight when determining the lease term if the contract contains options to extend or terminate the lease.

3) Impacts on financial statements

On transition to IFRS 16, the Group recognised additional \$71,080 thousands of right-of-use assets and \$20,352 thousands of lease liabilities, recognising the difference from other non-current and current assets. When measuring lease liabilities, the Group discounted lease payments using its incremental borrowing rate at January 1, 2019. The weighted-average rate applied is 1.02%.

The explanation of differences between operating lease commitments disclosed at the end of the annual reporting period immediately preceding the date of initial application, and lease liabilities recognized in the statement of financial position at the date of initial application disclosed as follows:

	<b>January 1, 2019</b>
Operating lease commitment at December 31, 2018	\$ 6,337
Extension and termination options reasonably certain to be exercised	14,420
Discounted Interest expense	(405)
Lease liabilities recognized at January 1, 2019	<b>\$ 20,352</b>

(b) The impact of IFRS issued by IASB but not yet endorsed by the FSC

As of the date, the following IFRSs that have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

<b>New, Revised or Amended Standards and Interpretations</b>	<b>Effective date per IASB</b>
Amendments to IFRS 3 “Definition of a Business”	January 1, 2020
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”	Effective date to be determined by IASB
IFRS 17 “Insurance Contracts”	January 1, 2021
Amendments to IAS 1 and IAS 8 “Definition of Material”	January 1, 2020

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

Those which may be relevant to the Group are set out below:

<u>Issuance / Release Dates</u>	<u>Standards or Interpretations</u>	<u>Content of amendment</u>
October 31, 2018	Amendments to IAS 1 and IAS 8 “Definition of Material”	The amendments clarify the definition of material and how it should be applied by including in the definition guidance that until now has featured elsewhere in IFRS Standards. In addition, the explanations accompanying the definition have been improved. Finally, the amendments ensure that the definition of material is consistent across all IFRS Standards.

The Group is evaluating the impact of its initial adoption of the abovementioned standards or interpretations on its consolidated financial position and consolidated financial performance. The results thereof will be disclosed when the Group completes its evaluation.

**(4) Summary of significant accounting policies:**

**(a) Statement of compliance**

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (hereinafter referred to IFRS endorsed by the FSC) for a complete set of the annual consolidated financial statements.

Except the following accounting policies mentioned below, the significant accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2018. For the related information, please refer to note 4 of the consolidated financial statements for the year ended December 31, 2018

**(b) Basis of consolidation**

**(i) List of subsidiaries in the consolidated financial statements:**

<u>Name of investor</u>	<u>Name of subsidiary</u>	<u>Principal activity</u>	<u>Shareholding</u>		
			<u>March 31, 2019</u>	<u>December 31, 2018</u>	<u>March 31, 2018</u>
The Company	BIOTEQUE MEDICAL CO., LTD.	Investment activities	100.00 %	100.00 %	100.00 %
The Company	CHUNGTEX INVESTMENT CO., LTD	Investment activities	100.00 %	100.00 %	100.00 %
The Company	BIOTEQUE MEDICAL PHIL. INC.	Manufacturing and Trading of Medical equipment	100.00 %	100.00 %	100.00 %
BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	Trading of Medical equipment	100.00 %	100.00 %	100.00 %

**(ii) List of subsidiaries which are not included in the consolidated financial statements: None.**

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(c) Leases (applicable from January 1, 2019)

(i) Identifying a lease

At inception of a contract, the Group assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether:

- the contract involves the use of an identified asset – this may be specified explicitly or implicitly, and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; and
- the Group has the right to obtain substantially all of the economic benefits from use of the asset throughout the period of use; and
- the Group has the right to direct the use of the asset. The Group has the right to direct the use of the asset when it has the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of an asset if either:
  - the Group has the right to operate the asset; or
  - the Group designed the asset in a way that predetermines how and for what purpose it will be used.

At inception or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. However, for the leases of land and buildings in which it is a lessee, the Group has elected not to separate non-lease components and account for the lease and non-lease components as a single lease component.

(ii) As a lessee

The Group recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be reliably determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the following:

- fixed payments;
- variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable under a residual value guarantee; and
- payments for purchase or termination options that are reasonably certain to be exercised.

The lease liability is measured at amortized cost using the effective interest method. It is remeasured when:

- there is a change in future lease payments arising from the change in an index or rate; or
- there is a change in the Group's estimate of the amount expected to be payable under a residual value guarantee; or
- there is a change of its assessment on whether it will exercise a purchase, extension or termination option; or
- there is any lease modifications

When the lease liability is remeasured, other than lease modifications, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or in profit and loss if the carrying amount of the right-of-use asset has been reduced to zero.

When the lease liability is remeasured to reflect the partial or full termination of the lease for lease modifications that decrease the scope of the lease, the Group accounts for the remeasurement of the lease liability by decreasing the carrying amount of the right-of-use asset to reflect the partial or full termination of the lease, and recognize in profit or loss any gain or loss relating to the partial or full termination of the lease.

The Group presents right-of-use assets that do not meet the definition of investment and lease liabilities as a separate line item respectively in the statement of financial position.

(d) **Income taxes**

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of International Financial Reporting Standards 34, Interim Reporting.

Income tax expenses for the period are best estimated by multiplying pre-tax income for the interim reporting period by the effective annual tax rate as forecasted by the management. This should be recognized fully as tax expense for the current period.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(e) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year.

**(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:**

The preparation of the consolidated financial statements in conformity with the Regulations and IFRSs (in accordance with IAS 34 “Interim Financial Reporting” and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The preparation of the consolidated financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2018. For the related information, please refer to note 5 of the consolidated financial statements for the year ended December 31, 2018.

**(6) Explanation of significant accounts:**

Except for the following disclosures, there is no significant difference as compared with those disclosed in the consolidated financial statements for the year ended December 31, 2018. Please refer to Note 6 of the 2018 annual consolidated financial statements.

(a) Cash and cash equivalents

	<b>March 31, 2019</b>	<b>December 31, 2018</b>	<b>March 31, 2018</b>
Cash on hand	\$ 678	509	435
Cash in bank	895,171	757,584	850,458
RP bills	<u>170,081</u>	<u>168,508</u>	<u>157,147</u>
Cash and cash equivalents in the consolidated statement of cash flows	<b><u>\$ 1,065,930</u></b>	<b><u>926,601</u></b>	<b><u>1,008,040</u></b>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

- (b) Current financial assets at fair value through profit or loss

	<u>March 31, 2019</u>	<u>December 31, 2018</u>	<u>March 31, 2018</u>
<b>Financial assets designated as at fair value through profit or loss:</b>			
RP bills	\$ 30,593	30,308	28,272
<b>Mandatorily measured at fair value through profit or loss:</b>			
Non-derivative financial assets			
Money market funds and bond funds	143,511	143,167	143,287
Stock listed on domestic markets	<u>3,119</u>	<u>2,850</u>	<u>1,445</u>
Total	<u>\$ 177,223</u>	<u>176,325</u>	<u>173,004</u>

- (i) For credit risk and market risk, please refer to note 6(q).  
(ii) The financial assets of the Group were not collateralized.

- (c) Non-current financial assets at fair value through other comprehensive income

	<u>March 31, 2019</u>	<u>December 31, 2018</u>	<u>March 31, 2018</u>
<b>Equity investments at fair value through other comprehensive income:</b>			
Stock listed on domestic markets	<u>\$ 222</u>	<u>237</u>	<u>307</u>

- (i) Equity investments at fair value through other comprehensive income

The Group designated the investments shown above as equity securities at fair value through other comprehensive income because these equity securities represent those investments that the Group intends to hold for long-term for strategic purposes.

There were no disposals of strategic investments and transfers of any cumulative gain or loss within equity relating to these investments as of March 31, 2019 and 2018.

- (ii) For credit risk and market risk, please refer to note 6(q).  
(iii) The financial assets of the Group were not collateralized.

(Continued)



**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

## (d) Notes and trade receivables

	<u>March 31, 2019</u>	<u>December 31, 2018</u>	<u>March 31, 2018</u>
Notes receivable	\$ 70,595	71,638	72,370
Trade receivables	204,898	211,038	209,299
Less: Loss allowance	-	-	-
	<u>\$ 275,493</u>	<u>282,676</u>	<u>281,669</u>

The Group applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due, as well as incorporated forward looking information. The loss allowance provision were determined as follows:

	<u>March 31, 2019</u>		
	<u>Gross carrying amount</u>	<u>Weighted- average loss rate</u>	<u>Loss allowance provision</u>
Current	\$ 262,555	-	-
1 to 30 days past due	12,938	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	-	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	8.62 %	-
151 to 180 days past due	-	19.34 %	-
More than 181 days past due	-	100 %	-
	<u>\$ 275,493</u>		<u>-</u>
	<u>December 31, 2018</u>		
	<u>Gross carrying amount</u>	<u>Weighted- average loss rate</u>	<u>Loss allowance provision</u>
Current	\$ 265,215	-	-
1 to 30 days past due	17,461	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	-	-	-
91 to 120 days past due	-	-	-
121 to 150 days past due	-	9.40 %	-
151 to 180 days past due	-	20.86 %	-
More than 181 days past due	-	100 %	-
	<u>\$ 282,676</u>		<u>-</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

	March 31, 2018		
	Gross carrying amount	Weighted- average loss rate	Loss allowance provision
Current	\$ 263,675	-	-
1 to 30 days past due	9,278	-	-
31 to 60 days past due	2,134	-	-
61 to 90 days past due	2,252	-	-
91 to 120 days past due	4,312	-	-
121 to 150 days past due	18	-	-
151 to 180 days past due	-	24.35 %	-
More than 181 days past due	-	100 %	-
	<u>\$ 281,669</u>		<u>-</u>

## (e) Inventories

	March 31, 2019	December 31, 2018	March 31, 2018
Raw materials	\$ 170,096	169,502	123,721
Work in progress	54,264	55,222	47,285
Finished goods	34,392	37,501	13,402
Merchandise	2,614	3,057	1,342
Raw materials in transit	17,946	16,452	23,163
	<u>\$ 279,312</u>	<u>281,734</u>	<u>208,913</u>

Except for cost of goods sold and inventories recognized as operating cost, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	Three months ended March 31, 2019	Three months ended March 31, 2018
Gains on physical inventory	\$ 244	410
Losses on valuation of inventories	(1,158)	-
	<u>\$ (914)</u>	<u>410</u>

The inventories of the Group were not collateralized.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(f) Property, plant and equipment

The cost and accumulated depreciation of the property, plant and equipment of the Group for the three months ended March 31, 2019 and 2018 were as follows:

	<u>Land</u>	<u>Building and structures</u>	<u>Machinery and equipment</u>	<u>Transportation equipment</u>	<u>Office equipment</u>	<u>Other equipment</u>	<u>Construction in progress</u>	<u>Total</u>
Cost:								
Balance at January 1, 2019	\$ 91,834	752,516	697,043	9,670	20,672	140,591	7,393	1,719,719
Additions	-	2,585	3,415	-	57	2,109	2,273	10,439
Reclassification (Note)	-	-	7,197	-	-	1,164	-	8,361
Effect of changes in foreign exchange rates	-	(1,577)	308	5	5	139	20	(1,100)
Balance at March 31, 2019	<u>\$ 91,834</u>	<u>753,524</u>	<u>707,963</u>	<u>9,675</u>	<u>20,734</u>	<u>144,003</u>	<u>9,686</u>	<u>1,737,419</u>
Balance at January 1, 2018	\$ 91,834	733,352	676,379	9,066	19,570	114,377	6,738	1,651,316
Additions	-	-	542	-	13	6,040	112	6,707
Disposals	-	-	(660)	-	-	(78)	-	(738)
Reclassification (Note)	-	6,136	162	-	-	2,126	(6,136)	2,288
Effect of changes in foreign exchange rates	-	(7,450)	(2,288)	(24)	(33)	(885)	(11)	(10,691)
Balance at March 31, 2018	<u>\$ 91,834</u>	<u>732,038</u>	<u>674,135</u>	<u>9,042</u>	<u>19,550</u>	<u>121,580</u>	<u>703</u>	<u>1,648,882</u>
Accumulated depreciation and impairment loss:								
Balance at January 1, 2019	\$ -	194,651	455,755	5,224	17,436	101,919	-	774,985
Depreciation	-	4,488	10,933	241	328	5,340	-	21,330
Effect of changes in foreign exchange rates	-	69	64	2	3	62	-	200
Balance at March 31, 2019	<u>\$ -</u>	<u>199,208</u>	<u>466,752</u>	<u>5,467</u>	<u>17,767</u>	<u>107,321</u>	<u>-</u>	<u>796,515</u>
Balance at January 1, 2018	\$ -	174,326	412,932	4,318	16,252	84,380	-	692,208
Depreciation	-	4,902	10,639	210	250	3,688	-	19,689
Disposals	-	-	(568)	-	-	(40)	-	(608)
Effect of changes in foreign exchange rates	-	(374)	(289)	(15)	(16)	(294)	-	(988)
Balance at March 31, 2018	<u>\$ -</u>	<u>178,854</u>	<u>422,714</u>	<u>4,513</u>	<u>16,486</u>	<u>87,734</u>	<u>-</u>	<u>710,301</u>
Carrying amounts:								
Balance at January 1, 2019	<u>\$ 91,834</u>	<u>557,865</u>	<u>241,288</u>	<u>4,446</u>	<u>3,236</u>	<u>38,672</u>	<u>7,393</u>	<u>944,734</u>
Balance at March 31, 2019	<u>\$ 91,834</u>	<u>554,316</u>	<u>241,211</u>	<u>4,208</u>	<u>2,967</u>	<u>36,682</u>	<u>9,686</u>	<u>940,904</u>
Balance at January 1, 2018	<u>\$ 91,834</u>	<u>559,026</u>	<u>263,447</u>	<u>4,748</u>	<u>3,318</u>	<u>29,997</u>	<u>6,738</u>	<u>959,108</u>
Balance at March 31, 2018	<u>\$ 91,834</u>	<u>553,184</u>	<u>251,421</u>	<u>4,529</u>	<u>3,064</u>	<u>33,846</u>	<u>703</u>	<u>938,581</u>

(Note) Prepayments for business facilities were reclassified as property, plant and equipment.

As of March 31, 2019, December 31 and March 31, 2018, the property, plant and equipment of the Group had been pledged as collateral for borrowings; please refer to note 8.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

## (g) Right-of-use assets

The Group leases many assets including land and buildings. Information about leases for which the Group as a lessee is presented below:

	<u>Land</u>	<u>Buildings and structures</u>	<u>Total</u>
Cost:			
Balance at January 1, 2019	\$ -	-	-
Effects of retrospective application	50,728	20,352	71,080
Effect of changes in foreign exchange rates	<u>148</u>	<u>4</u>	<u>152</u>
Balance at March 31, 2019	<u>\$ 50,876</u>	<u>20,356</u>	<u>71,232</u>
Accumulated depreciation:			
Balance at January 1, 2019	\$ -	-	-
Depreciation for the year	<u>183</u>	<u>1,238</u>	<u>1,421</u>
Balance at March 31, 2019	<u>\$ 183</u>	<u>1,238</u>	<u>1,421</u>
Carrying amount:			
Balance at March 31, 2019	<u>\$ 50,693</u>	<u>19,118</u>	<u>69,811</u>

## (h) Short-term and long-term borrowings

## (i) Short-term borrowings

	<u>March 31, 2019</u>	<u>December 31, 2018</u>	<u>March 31, 2018</u>
Unsecured bank loans	\$ -	<u>25,000</u>	<u>80,000</u>
Unused credit lines	<u>\$ 923,390</u>	<u>663,345</u>	<u>915,995</u>
Range of interest rate	<u>-</u>	<u>1%</u>	<u>0.91%</u>

## (ii) Long-term borrowings

	<u>March 31, 2019</u>	<u>December 31, 2018</u>	<u>March 31, 2018</u>
Unsecured bank loans	\$ 33,378	46,080	76,414
Less: Current portion	<u>(28,243)</u>	<u>(35,840)</u>	<u>(44,878)</u>
	<u>\$ 5,135</u>	<u>10,240</u>	<u>31,536</u>
Unused credit lines	<u>\$ 30,810</u>	<u>30,720</u>	<u>29,110</u>
Range of interest rate	<u>3.75%~4.49%</u>	<u>3.75%~4.49%</u>	<u>2.70%~3.77%</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

Parts of the Group's long-term borrowings will be settled in foreign currency. The details of foreign long-term liabilities were as follows:

	<b>March 31, 2019</b>	<b>December 31, 2018</b>	<b>March 31, 2018</b>
USD (thousand dollars)	\$ <u>1,083</u>	<u>1,500</u>	<u>2,625</u>
Convert to NTD	\$ <u>33,378</u>	<u>46,080</u>	<u>76,414</u>

As of March 31, 2019, the remaining balance of the borrowing due were as follows:

<u>Period</u>	<u>Amount</u>
2019.4.1 ~ 2020.3.31	\$ 28,243
2020.4.1 ~ 2021.3.31	<u>5,135</u>
	<u>\$ 33,378</u>

For the collateral for borrowing, please refer to note 8.

(i) Lease liabilities

	<b>March 31, 2019</b>		
	<b>Future minimum lease payments</b>	<b>Interest</b>	<b>Present value of minimum lease payments</b>
Less than one year	\$ 5,046	169	4,877
Between one and five years	<u>14,456</u>	<u>203</u>	<u>14,253</u>
	<u>\$ 19,502</u>	<u>372</u>	<u>19,130</u>
Current	<u>\$ 5,046</u>	<u>169</u>	<u>4,877</u>
Non-current financial assets	<u>\$ 14,456</u>	<u>203</u>	<u>14,253</u>

There were no significant issues, repurchases and repayments of lease liabilities for the three months ended March 31, 2019.

The amounts recognized in profit or loss were as follows:

	<b>For the three months ended March 31, 2019</b>
Interest on lease liabilities	\$ <u>33</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

The amounts recognized in the statement of cash flows for the Group was as follows:

	<b>For the three months ended March 31, 2019</b>
Total cash outflow for leases	<b>\$ <u>1,257</u></b>

(i) Leases of land , buildings and structures

As of March 31, 2019, the Group leases land , buildings and structures for its office space and parking lot. The leases of office space typically run for a period of 2 to 6 years. Some leases include an option to renew the lease for an additional period of 2 to 3 years after the end of the contract term.

Some leases of equipment contain extension options exercisable. These leases are negotiated and monitored by local management, and accordingly, contain a wide range of different terms and conditions. The extension options held are exercisable only by the Group and not by the lessors. In which leasee is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

(j) Employee benefits

(i) Defined benefit plans

Management believes that there was no material volatility of the market, no material reimbursement and settlement or other material one time events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2018 and 2017.

The expenses recognized in profit or loss for the Group were as follows:

	<b>Three months ended March 31, 2019</b>	<b>Three months ended March 31, 2018</b>
Operating costs	\$ 76	70
Operating expenses	<u>146</u>	<u>235</u>
	<b>\$ <u>222</u></b>	<b><u>305</u></b>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(ii) Defined contribution plans

The Group's expenses under the pension plan cost to the Bureau of Labor Insurance for the three months ended March 31, 2019 and 2018 were as follows:

	<b>Three months ended March 31, 2019</b>	<b>Three months ended March 31, 2018</b>
Operating costs	\$ 1,346	1,349
Operating expenses	604	570
	<b><u>\$ 1,950</u></b>	<b><u>1,919</u></b>

(iii) The Group's subsidiaries incorporated in the Philippine have a defined contribution plan, wherein a monthly contribution to an independent fund, administered by the government in accordance with the pension regulations in the Republic of the Philippines, are based on certain percentage of employees' monthly salaries and wages. For the three months ended March 31, 2019, the Group recognized the pension costs amounting to \$16 thousand in accordance with the pension regulations.

(k) Income taxes

The amounts of income tax were as follows:

	<b>Three months ended March 31, 2019</b>	<b>Three months ended March 31, 2018</b>
Current tax expenses	<b><u>\$ 27,805</u></b>	<b><u>22,623</u></b>

The Company's income tax returns for the years through 2017 were examined by the Taipei National Tax Administration.

(l) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the periods from January 1 to March 31, 2019 and 2018. For the related information, please refer to note 6(l) of the consolidated financial statements for the year ended December 31, 2018.

As of March 31, 2019 and 2018, the Company's authorized share capital consisted of \$1,200,000 thousand shares of ordinary share, with \$10 dollars par value per share, of which \$69,298 thousand shares, was issued and outstanding. All issued shares were paid up upon issuance.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(i) Capital surplus

Balance of capital surplus at the reporting date were as follows:

	<b>March 31, 2019</b>	<b>December 31, 2018</b>	<b>March 31, 2018</b>
Share capital	<u>\$ 315,168</u>	<u>315,168</u>	<u>315,168</u>

According to the R.O.C. Company Act, capital surplus can only be used to offset a deficit, and only the realized capital surplus can be used to increase the common stock or be distributed as cash dividends. The aforementioned realized capital surplus includes capital surplus resulting from premium on issuance of capital stock and earnings from donated assets received. According to the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, capital increases by transferring capital surplus in excess of par value should not exceed 10% of the total common stock outstanding.

(ii) Retained earnings

The Company's Articles of Incorporation stipulate that 10% of the annual income or earnings, after deducting any accumulated deficit, shall be set aside as a legal reserve. When the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. The remaining balance, if any, shall be appropriated as special reserve or distributed as shareholders' equity, which is to be proposed by the board of directors during the shareholders' meeting for approval, in accordance with the relevant laws and regulations.

The Company's industry is in its development stage. In order to achieve its sustainable development goals, the Company is aggressively developing and introducing new products. Thus, the growth stage requires funds to further expand the Company's production lines to facilitate the growth in a next few years. The Company planned to adopt the policy for equalization of dividends to be paid in shares or cash, which is more than 20%, in general. However, if there is a significant capital expenditure in the future (when the purchasing amount of fixed assets or the investment of production offshoring exceed 10% of the paid-in capital), all the cash dividend can be converted into shares, with the approval from the shareholders.

When the Board of Directors decides to distribute the dividend and if the Company's market price of common stock is lower than the par value from Over The Counter Market on the previous day, the cash dividend can be fully or partially paid.

1) Legal reserve

According to the amendment of the R.O.C. Company Act in January 2012, the Company must retain 10% of its after-tax annual earnings as legal reserve until such retention equals the amount of total capital. When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

(Continued)



**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

2) Special reserve

In accordance with Ruling No. 1010012865 issued by the FSC on April 6, 2012, a portion of current-period earnings and undistributed prior-period earnings shall be reclassified as special earnings reserve during earnings distribution. The amount to be reclassified should equal the current-period total net reduction of other shareholders' equity. Similarly, a portion of undistributed prior-period earnings shall be reclassified as special earnings reserve (which does not qualify for earnings distribution) to account for cumulative changes to other shareholders' equity pertaining to prior periods. The amounts of subsequent reversals pertaining to the net reduction of other shareholders' equity shall qualify for additional distributions.

3) Earnings distribution

On March 15, 2019, the Company's board of directors resolved to appropriate the 2018 earnings. On June 15, 2018, the shareholder's meeting resolved to distribute the 2017 earnings. These earnings were appropriated as follows:

	2018		2017	
	Amount per share	Amount	Amount per share	Amount
Dividends distributed to ordinary shareholders:				
Cash of retained earnings	\$ 4.00	\$ <u>277,193</u>	3.50	<u>242,544</u>

(iii) OCI accumulated in reserves, net of tax

	Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial asset measured at fair value through other comprehensive income	Total	
Balance at January 1, 2019	\$ 12,259	(1,315)	10,944	
Exchange differences on foreign operations	1,749	-	1,749	
Unrealized gains (losses) from financial asset measured at fair value through other comprehensive income	-	(14)	(14)	
Balance at March 31, 2019	<u>\$ 14,008</u>	<u>(1,329)</u>	<u>12,679</u>	
	Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial asset measured at fair value through other comprehensive income	Unrealized gains (losses) on available-for-sale financial assets	Total
Balance at January 1, 2018	\$ (5,235)	-	(1,224)	(6,459)
Effects of retrospective application	-	(1,224)	1,224	-
Balance at January 1, 2018 after adjustments	(5,235)	(1,224)	-	(6,459)
Exchange differences on foreign operations	(12,316)	-	-	(12,316)
Unrealized gains (losses) from financial asset measured at fair value through other comprehensive income	-	(21)	-	(21)
Balance at March 31, 2018	<u>\$ (17,551)</u>	<u>(1,245)</u>	<u>-</u>	<u>(18,796)</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(m) Earnings per share

The Company's earnings per share were calculated as follows:

(i) Basic earnings per share

	<b>Three months ended March 31, 2019</b>	<b>Three months ended March 31, 2018</b>
Profit attributable to ordinary shareholders of the Company	\$ <u>115,997</u>	<u>82,871</u>
Weighted-average number of ordinary shares	<u>69,298</u>	<u>69,298</u>
Basic earnings per share (express in New Taiwan Dollar)	\$ <u>1.67</u>	<u>1.20</u>

(ii) Diluted earnings per share

	<b>Three months ended March 31, 2019</b>	<b>Three months ended March 31, 2018</b>
Profit attributable to ordinary shareholders of the Company	\$ <u>115,997</u>	<u>82,871</u>
Weighted-average number of ordinary shares (basic)	69,298	69,298
Effect of employee remuneration (in thousands)	<u>262</u>	<u>234</u>
Weighted-average number of ordinary shares (diluted)	<u>69,560</u>	<u>69,532</u>
Diluted earnings per share (express in New Taiwan Dollar)	\$ <u>1.67</u>	<u>1.19</u>

(n) Revenue from contracts with customers

(i) Disaggregation of revenue

	<b>Three months ended March 31, 2019</b>	<b>Three months ended March 31, 2019</b>
Primary geographical markets:		
Asia	\$ 198,630	156,246
South America	55,136	46,181
North America	61,224	34,991
Others	<u>125,724</u>	<u>138,490</u>
Total	\$ <u>440,714</u>	<u>375,908</u>
Major products service lines:		
Manufacturing, trading and selling of medical equipment	\$ <u>440,714</u>	<u>375,908</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(ii) Contract balances

	<u>March 31, 2019</u>	<u>December 31, 2018</u>	<u>March 31, 2018</u>
Notes and accounts receivable	\$ 275,493	282,676	281,669
Less: allowance for impairment	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 275,493</u>	<u>282,676</u>	<u>281,669</u>
	<u>March 31, 2019</u>	<u>December 31, 2018</u>	<u>March 31, 2018</u>
Current contract liabilities	<u>\$ 51,017</u>	<u>33,923</u>	<u>23,106</u>

For details on accounts receivable and allowance for impairment, please refer to note 6(d).

The amount of revenue recognized for the three months ended March 31, 2019 and 2018 that was included in the contract liability balance at the beginning of the period were \$28,759 thousand and \$13,389 thousand, respectively.

The major change in the balance of contract assets and liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received.

(o) Remuneration to employees, directors and supervisors

According to the Article of Association, once the Company has annual profit, it should appropriate no less than 5% of the profit to its employees and 1.6% or less to its directors and supervisors.

The Company's estimated remuneration is as follows:

	<u>Three months ended March 31,</u>	
	<u>2019</u>	<u>2018</u>
Employee remuneration	\$ 7,709	5,623
Directors' and supervisors' remuneration	<u>2,467</u>	<u>1,799</u>
	<u>\$ 10,176</u>	<u>7,422</u>

The amount of employee remuneration, and directors' and supervisors' remuneration were estimated based on profit before tax, net of the amount of the remuneration, and multiplied by the rule of Company's Article of Association. The above remuneration were included in the operating expenses of the three months ended March 31, 2019 and 2018. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

For the year ended December 31, 2018 and 2017 the Company accrued and recognized its employee remuneration amounting to \$27,440 thousand and \$20,957 thousand, and directors' and supervisors' remuneration amounting to \$8,781 thousand and \$6,706 thousand, respectively. There was no differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements.

The related information mentioned above can be found on websites such as the Market Observation Post System.

- (p) Non-operating income and expenses
- (i) Other income

	<b>Three months ended March 31</b>	
	<b>2019</b>	<b>2018</b>
Interest income:		
Interest income from RP bills	\$ 1,088	805
Interest income from funds	89	89
Interest income from deposit	3	3
Interest income from bank deposit	680	243
	1,860	1,140
Subsidy revenue	521	263
Compensation income	-	573
Others	1,069	1,119
	<b>\$ 3,450</b>	<b>3,095</b>

- (ii) Other gains and losses

	<b>Three months ended March 31</b>	
	<b>2019</b>	<b>2018</b>
Foreign exchange gains (losses)	\$ 4,306	(10,050)
Gains (losses) on financial assets at fair value through profit or loss	613	(1)
Losses on disposal of property plant and equipment	-	(26)
Others	(35)	(137)
	<b>\$ 4,884</b>	<b>(10,214)</b>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(iii) Finance costs

	<b>Three months ended March 31</b>	
	<b>2019</b>	<b>2018</b>
Interest expense on bank borrowings	\$ (442)	(785)
Interest expense on lease liabilities	(33)	-
	<b>\$ (475)</b>	<b>(785)</b>

(q) Financial instruments

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information please refer to note 6(r) of the consolidated financial statements for the year ended December 31, 2018. Regarding how the financial instruments are considered to have low credit risk, please refer to note 4(g).

(i) Credit risk

1) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

2) Concentration of credit risk

As of March 31, 2019, December 31 and March 31, 2018, 33%, 30% and 26% of the Group's accounts receivable were concentrated on 2 specific customers, respectively.

3) Receivables securities

For credit risk exposure of note and trade receivables, please refer to note 6(d).

Other financial assets at amortized costs includes other receivables.

All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses.

For the three months ended March 31, 2019 and 2018, the impairment loss are not recognized and reserved.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(ii) Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments and excluding the impact of netting agreements.

	<u>Carrying amount</u>	<u>Contractual cash flows</u>	<u>within 1 year</u>	<u>1-2 years</u>	<u>2-5 years</u>	<u>Over 5 years</u>
<b>March 31, 2019</b>						
Non-derivative financial liabilities						
Long-term liabilities, current portion	\$ 28,243	29,552	29,552	-	-	-
Notes payable	39,223	39,223	39,223	-	-	-
Accounts payable	78,507	78,507	78,507	-	-	-
Other payables	37,569	37,569	37,569	-	-	-
Payables on machinery and equipment	3,347	3,347	3,347	-	-	-
Long-term borrowings	5,135	5,328	-	5,328	-	-
Lease liabilities (current and non current)	19,130	19,502	5,046	5,063	9,393	-
	<u>\$ 211,154</u>	<u>213,028</u>	<u>193,244</u>	<u>10,391</u>	<u>9,393</u>	<u>-</u>
<b>December 31, 2018</b>						
Non-derivative financial liabilities						
Short-term borrowing	\$ 25,000	25,125	25,125	-	-	-
Long-term liabilities, current portion	35,840	37,681	37,681	-	-	-
Notes payable	37,807	37,807	37,807	-	-	-
Accounts payable	75,256	75,256	75,256	-	-	-
Other payables	35,634	35,634	35,634	-	-	-
Payables on machinery and equipment	5,941	5,941	5,941	-	-	-
Long-term borrowings	10,240	10,624	-	10,624	-	-
	<u>\$ 225,718</u>	<u>228,068</u>	<u>217,444</u>	<u>10,624</u>	<u>-</u>	<u>-</u>
<b>March 31, 2018</b>						
Non-derivative financial liabilities						
Short-term borrowing	\$ 80,000	80,413	80,413	-	-	-
Long-term liabilities, current portion	44,878	47,291	47,291	-	-	-
Notes payable	38,729	38,729	38,729	-	-	-
Accounts payable	69,122	69,122	69,122	-	-	-
Other payables	35,885	35,885	35,885	-	-	-
Payables on machinery and equipment	2,294	2,294	2,294	-	-	-
Long-term borrowings	31,536	32,596	-	27,613	4,983	-
	<u>\$ 302,444</u>	<u>306,330</u>	<u>273,734</u>	<u>27,613</u>	<u>4,983</u>	<u>-</u>

The Group does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amount.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(iii) Market risk

1) Currency risk

The Group's significant exposure to foreign currency risk was as follows:

	March 31, 2019			December 31, 2018			March 31, 2018			
	Foreign currency	Exchange rate	NTD	Foreign currency	Exchange rate	NTD	Foreign currency	Exchange rate	NTD	
<b>Financial assets</b>										
<u>Monetary items</u>										
USD	\$	12,946	30.81	398,864	14,218	30.72	436,778	15,230	29.11	443,354
EUR		1,515	34.61	52,444	1,196	35.24	42,159	925	35.94	33,233
JPY		63,291	0.2777	17,573	54,721	0.2786	15,242	170,836	0.2744	46,869
PHP		65,341	0.6020	39,335	53,363	0.5990	31,964	50,336	0.5725	28,817
CNY		12,088	4.594	55,533	13,352	4.473	59,725	11,035	4.647	51,280
<u>Investments accounted for using equity method</u>										
USD		18,835	30.81	580,300	18,224	30.72	559,855	17,018	29.11	495,401
PHP		15,327	0.6020	9,227	11,833	0.5990	7,088	7,155	0.5725	4,096
<b>Financial liabilities</b>										
<u>Monetary items</u>										
USD		1,199	30.81	36,948	1,044	30.72	32,068	899	29.11	26,168
EUR		166	34.61	5,753	296	35.24	10,414	267	35.94	9,605
JPY		32,094	0.2777	8,911	43,942	0.2786	12,240	29,876	0.2744	8,196
PHP		15,796	0.6020	9,509	27,482	0.5990	16,462	15,766	0.5725	9,026

The Group's exposure to foreign currency risk arise from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, trade receivables and trade payables that are denominated in foreign currency.

A strengthening (weakening) of 1% of the NTD against the foreign currency for the three months ended March 31, 2019 and 2018 would have increased (decreased), the net profit before tax by \$5,026 thousand and \$5,506 thousand, respectively. The analysis is performed on the same basis for 2018.

Since the Group has many kinds of functional currency, the information on foreign exchange gain (loss) on monetary items is disclosed by total amount. For the three months ended March 31, 2019 and 2018, foreign exchange gains (losses) (including realized and unrealized portions) amounted to \$4,306 thousand and \$(10,050) thousand, respectively.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

2) Interest rate analysis

Please refer to the notes on liquidity risk management and interest rate exposure of the Group's financial assets and liabilities.

The following sensitivity analysis is based on the exposure to the interest rate risk of non-derivative financial instruments on the reporting date. Regarding assets with variable interest rates, the analysis is based on the assumption that the amount of assets outstanding at the reporting date was outstanding throughout the year. The rate of change is expressed as the interest rate increases or decreases by 1% when reporting to management internally, which also represents the Group management's assessment of the reasonably possible interest rate change.

If the interest rate had increased / decreased by 1% basic points the Group's net profit before tax would have decreased / increased by \$334 thousand and \$1,564 thousand for the three months ended March 31, 2019 and 2018 with all other variable factors remain constant. This is mainly due to the Group's borrowing at floating rates.

3) Other market price risk

For the three months ended March 31, 2019 and 2018, the sensitivity analyzes for the changes in the securities price at the reporting date were performed using the same basis for the profit and loss as illustrated below:

	Three months ended March 31			
	2019		2018	
	Other comprehensive income before tax	Net profit before tax	Other comprehensive income before tax	Net profit before tax
Prices of securities at the reporting date				
Increasing 1%	\$ <u>2</u>	<u>31</u>	<u>3</u>	<u>14</u>
Decreasing 1%	\$ <u>(2)</u>	<u>(31)</u>	<u>(3)</u>	<u>(14)</u>

(iv) Fair value of financial instruments

1) Fair value hierarchy

The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows, however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and for equity investments that has no quoted prices in the active markets and whose fair value cannot be reliably measured, disclosure of fair value information is not required:

(Continued)





**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

	March 31, 2018				Total
	Book value	Fair value			
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 144,732	144,732	-	-	144,732
Designated at fair value through profit or loss	<u>28,272</u>	<u>28,272</u>	-	-	<u>28,272</u>
Subtotal	<u>173,004</u>	<u>173,004</u>	-	-	<u>173,004</u>
Financial assets at fair value through other comprehensive income					
Stocks listed on domestic markets	<u>307</u>	<u>307</u>	-	-	<u>307</u>
Financial assets measured at amortized cost					
Cash and cash equivalents	1,008,040	-	-	-	-
Notes and accounts receivables	281,669	-	-	-	-
Other financial assets	<u>3,603</u>	-	-	-	-
Subtotal	<u>1,293,312</u>	-	-	-	-
Total	<u>\$ 1,466,623</u>	<u>173,311</u>	-	-	<u>173,311</u>
Financial liabilities measured at amortized cost					
Short-term borrowings	\$ 80,000	-	-	-	-
Long-term liabilities, current portion	44,878	-	-	-	-
Notes and accounts payables	107,851	-	-	-	-
Other payable	35,885	-	-	-	-
Payables on machinery and equipment	2,294	-	-	-	-
Long-term borrowings	<u>31,536</u>	-	-	-	-
Total	<u>\$ 302,444</u>	-	-	-	-

2) Valuation techniques for financial instruments measured at fair value

A financial instrument is regarded as being quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm's-length basis. Whether transactions are taking place 'regularly' is a matter of judgment and depends on the facts and circumstances of the market for the instrument.

Quoted market prices may not be indicative of the fair value of an instrument if the activity in the market is infrequent, the market is not well-established, only small volumes are traded, or bid-ask spreads are very wide. Determining whether a market is active involves judgment.

When the financial instruments of the Group is traded in an active market, its fair value is illustrated by the category and nature as follows:

The fair value of listed stocks and funds traded in an active market is based on the market quoted price.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

Measurements of fair value of financial instruments without an active market are based on valuation technique or quoted price from a competitor. Fair value, measured by using valuation technique that can be extrapolated from either similar financial instruments or discounted cash flow method or other valuation techniques, including models, is calculated based on available market date at the reporting date.

3) Categories and fair values of financial instruments

The Company strives to use market observable inputs when measuring assets and liabilities. Different levels of the fair value hierarchy to be used in determining the fair value of financial instruments are as follows:

- a) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- b) Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c) Level 3: inputs for the assets or liability that are not based on observable market data (unobservable inputs).

For the three months ended March 31, 2019 and 2018, there were no change on the fair value hierarchy of financial asset.

(r) Financial risk management

There were no significant changes in the Group's financial risk management and policies as disclosed in note 6(s) of the consolidated financial statements for the year ended December 31, 2018.

(s) Capital management

Management believes that the objectives, policies and processes of capital management of the Group has been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2018. Also, management believes that there were no significant changes in the Group's capital management information as disclosed for the year ended December 31, 2018. Please refer to Note 6(t) of the consolidated financial statements for the year ended December 31, 2018 for further details.

(t) Investing and financing activities not affecting the current cash flow

The Group's financial activities which did not affect the current cash flow for the three months ended March 31, 2019 and 2018, were as follows:

	January 1, 2019	Cash flows	<u>Non-cash changes</u> Foreign exchange movement	March 31, 2019
Long-term borrowings (including current portion)	\$ 46,080	(12,844)	142	33,378
Lease liabilities (current and non current)	20,352	(1,224)	2	19,130
Total liabilities from financial activities	<u>\$ 66,432</u>	<u>(14,068)</u>	<u>144</u>	<u>52,508</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

	January 1, 2018	Cash flows	Non-cash changes		March 31, 2018
			Foreign exchange movement		
Long-term borrowings (including current portion)	\$ 81,895	(3,663)	(1,818)		76,414
Total liabilities from financial activities	\$ 81,895	(3,663)	(1,818)		76,414

**(7) Related-parties transactions:**

- (a) Names and relationship with related parties

Due to the absence of any transaction with related parties during the periods covered in the consolidated financial statements, the name and relationships of related parties have not been disclosed.

- (b) Significant transactions with related parties: None.

- (c) Key management personnel compensation

Key management personnel compensation were comprised as below:

	Three months ended March 31	
	2019	2018
Short-term employee benefits	\$ 5,636	4,716
Post-employment benefits	127	265
	<u>\$ 5,763</u>	<u>4,981</u>

**(8) Pledged assets:**

Pledged assets	Object	March 31, 2019	December 31, 2018	March 31, 2018
Other current financial assets:				
Restricted bank deposit	Purchase guarantee	\$ 601	601	601
Property, plant and equipment				
Land	Credit of short-term borrowings	91,834	91,834	91,834
Buildings and structures	Credit of short-term borrowings	189,751	191,729	197,663
Machinery and equipment	Credit of short-term borrowings	17,284	19,367	25,617
		<u>\$ 299,470</u>	<u>303,531</u>	<u>315,715</u>

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

**(9) Commitments and contingencies:**

## (a) Contingencies

In prior years, the Group entered into the license agreement which has expired with a supplier. On July 5, 2018, the supplier filed a complaint which has not completed accusing the Group. The Group assess there is no the significant impact on its consolidated financial statements.

## (b) Notes issued as guarantee

	March 31, 2019	December 31, 2018	March 31, 2018
Long-term borrowings	\$ <u>894,050</u>	<u>743,600</u>	<u>870,995</u>

## (c) The agreements for expansion of the factory and purchases of machinery and equipment

	March 31, 2019	December 31, 2018	March 31, 2018
Total contract price	\$ <u>110,092</u>	<u>140,761</u>	<u>45,176</u>
Paid amount	\$ <u>73,792</u>	<u>77,348</u>	<u>23,800</u>

**(10) Losses Due to Major Disasters: None****(11) Subsequent Events: None****(12) Other:**

- (a) A summary of current-period employee benefits, depreciation, and amortization, by function, is as follows:

By item	By function	Three months ended March 31, 2019			Three months ended March 31, 2018		
		Cost of sales	Operating expenses	Total	Cost of sales	Operating expenses	Total
Employee benefits							
Salary		49,345	22,740	72,085	44,033	14,575	58,608
Labor and health insurance		3,856	1,463	5,319	3,593	1,174	4,767
Pension		1,433	755	2,188	1,419	805	2,224
Remuneration of directors		-	1,847	1,847	-	1,359	1,359
Others		2,067	690	2,757	1,957	1,355	3,312
Depreciation		20,626	2,125	22,751	18,814	875	19,689
Amortization		226	465	691	426	600	1,026

## (b) Seasonality of operations

The Group's operations were not affected by seasonality or cyclicality factors.

(Continued)

## BIOTEQUE CORPORATION AND SUBSIDIARIES

### Notes to the Consolidated Financial Statements

#### (13) Other disclosures:

##### (a) Information on significant transactions:

The followings were the information on significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the Group for the three months ended March 31, 2019 :

##### (i) Leading to other parties:

(In thousands of dollars)

Number	Name of lender	Name of borrower	Account name	Related party	Highest balance of financing to other parties during the period (Note 3)	Ending balance (Note 3)	Amount of used loan facilities (Note 4)	Range of interest rates during the period	Purposes of fund financing for the borrower (Note 1)	Transaction amount for business between two parties	Reasons for short-term financing	Allowance for bad debt	Collateral		Individual funding loan limits (Note 2)	Maximum limit of fund financing (Note 2)
													Item	Value		
1	BIOTEQUE MEDICAL CO., LTD.	BIOTEQUE MEDICAL PHIL. INC	Accounts receivable from related parties	Yes	215,670 (USD 7,000)	215,670 (USD 7,000)	123,240 (USD 4,000)	2.00%	2	-	Working Capital	-	None	-	264,979 (Note 2)	264,979 (Note 2)

Note 1: Purposes of lending were as follows:

1. Business relationship
2. Short-term financing

Note 2: For entities in which the Company, directly or indirectly, owned 100% of their shares, the amount available for financing shall not exceed the net worth of the borrower.

Note 3: The maximum balance for the period and ending balance represent the amounts approved by the Board of Directors.

Note 4: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

##### (ii) Guarantees and endorsements for other parties:

(In thousands of dollars)

Number	Name of guarantor	Counter-party of guarantee and endorsement		Limitation on amount of guarantees and endorsements for a specific enterprise (Note 2)	Highest balance for guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	Ratio of accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 1)	Parent company/endorsements/ guarantees to third parties on behalf of subsidiary	Subsidiary endorsements/ guarantees to third parties on behalf of parent company	Endorsements/ guarantees to third parties on behalf of companies in Mainland China
		Name	Relationship with the Company (Note 3)										
1	The Company	BIOTEQUE MEDICAL CO., LTD.	4	207,894	30,810 (USD 1,000)	30,810 (USD 1,000)	-	-	1.27 %	346,491	Y	N	N
2	The Company	BIOTEQUE MEDICAL PHIL. INC	4	207,894	200,265 (USD 6,500)	200,265 (USD 6,500)	33,367 (USD 1,083)	-	8.24 %	346,491	Y	N	N

Note 1: The total amount for the guarantees and endorsements provided by the Company to external entities shall not exceed 50% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to external entities shall not exceed 50% of the Company's net worth.

Note 2: The total amount for the guarantees and endorsements provided by the Company to any individual entity shall not exceed 30% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to any individual entity shall not exceed 30% of the Company's net worth.

Note 3: Relationship with the Company

1. Ordinary business relationship.
2. An entity, directly and indirectly, owned more than 50% voting shares of a guarantor.
3. A guarantor, directly and indirectly, owned more than 50% voting shares of an entity.
4. An entity, directly and indirectly, owned more than 90% voting shares of a guarantor.
5. Fulfillment of contractual obligations by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.
6. An entity that is guaranteed and endorsed by all capital contributing shareholders in proportion to their shareholding percentages.
7. Peer engaged in the escrow of the sales contract on pre-sale house under the Consumer Protection Act.

(Continued)

**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

(iii) Information regarding securities held at the reporting date (subsidiaries, associates and joint ventures not included):

(In thousands of New Taiwan Dollars)

Name of holder	Category and name of security	Relationship with company	Account title	Ending balance				Remark
				Shares/Units (in thousands)	Carrying value	Percentage of ownership (%)	Fair value	
The Company	Capital Money Market Fund	None	Current financial assets at fair value through profit or loss	641	10,338	-	10,338	
"	Yuanta Wan Tai Money Market Fund	"	"	2,497	37,818	-	37,818	
"	Franklin Templeton Sinoam Money Market Fund	"	"	2,992	30,927	-	30,927	
"	Mega Diamond Money Market Fund	"	"	2,894	36,279	-	36,279	
"	Paradigm Pion Money Market Fund	"	"	1,970	22,754	-	22,754	
"	LEAD DATA INC.	"	Non-current financial assets at fair value through other comprehensive income	53	222	0.04	222	
CHUNGTEX INVESTMENT CO., LTD.	E.SUN FINANCIAL HOLDING COMPANY, LTD.	"	Current financial assets at fair value through profit or loss	32	756	-	756	
"	China Steel Corporation	"	"	11	278	-	278	
"	UNITED MICROELECTRONICS CORP.	"	"	10	116	-	116	
"	EVERGREEN MARINE CORP. (TAIWAN) LTD.	"	"	-	2	-	2	
"	TAISHIN FINANCIAL HOLDING CO., LTD.	"	"	64	896	-	896	
"	CHANG HWA CONNERCIAL BANK., LTD.	"	"	31	576	-	576	
"	EXCELSIOR MEDICAL CO., LTD	"	"	10	495	-	495	
"	PineBridge Emerging Market Corporate Strategy Bond Fund B	"	"	378	3,172	-	3,172	
"	Fuh Hwa Emerging Market High Yield Bond Fund B	"	"	412	2,223	-	2,223	
BIOTEQUE MEDICAL CO., LTD	Bonds with a rating of BBB- or better by the standard & poor's	"	"	-	30,593	-	30,593	

Note: If there are public markets prices, the fair value shall be evaluated by the last operating date of the accounting duration.

- (iv) Information regarding purchase or sale of securities for the period exceeding 300 million or 20% of the Company's paid-in capital: None.
- (v) Information on acquisition of real estate with purchase amount exceeding 300 million or 20% of the Company's paid-in capital: None.
- (vi) Information regarding receivables from disposal of real estate exceeding 300 million or 20% of the Company's paid-in capital: None.
- (vii) Information regarding related-parties purchases and/or sales exceeding 100 million or 20% of the Company's paid-in capital: None.

(Continued)

## BIOTEQUE CORPORATION AND SUBSIDIARIES

### Notes to the Consolidated Financial Statements

(viii) Information regarding receivables from related-parties exceeding 100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of company	Counter-party	Nature of relationship	Ending balance	Turnover rate	Overdue		Amounts received in subsequent period	Allowance for bad debts
					Amount	Action taken		
The Company	BIOTEQUE MEDICAL PHIL. INC.	Subsidiary	161,069	1.09	-	-	28,189	-

Note: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

(ix) Information regarding trading in derivative financial instruments: None.

(x) Significant transactions and business relationship between the parent company and its subsidiaries for the three months ended March 31, 2019:

(In thousands of New Taiwan Dollars)

No. (Note 1)	Name of company	Name of counter-party	Nature of relationship (Note 2)	Intercompany transactions				
				Account name	Amount	Trading terms	Percentage of the consolidated net revenue or total assets	
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Account receivables	146,773	OA 270	5.02%	
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Processing costs	8,510	There is no significant difference from translation terms with non-related parties.	1.93%	
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Other receivables	14,296		OA 270	0.49%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Account payables	14,972		OA 30	0.51%
1	BIOTEQUE MEDICAL CO., LTD.	BIOTEQUE MEDICAL PHIL. INC.	3	Other receivables	123,240	2%	4.22%	

Note 1: Company numbering as follows:

Parent company -- 0

Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary -- 1

Subsidiary to parent company -- 2

Subsidiary to subsidiary -- 3

Note 3: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

(b) Information on investees:

The following are the information on investees for the three months ended March 31, 2019 (excluding information on investees in Mainland China):

(In thousands of New Taiwan Dollars)

Name of investor	Name of investee	Location	Main businesses and products	Original investment amount		Balance as of March 31, 2019			Net income (losses) of investee	Share of profits (losses) of investee	Remark
				March 31, 2019	December 31, 2018	Shares (in thousands)	Percentage of ownership	Carrying value			
The Company	BIOTEQUE MEDICAL CO., LTD.	Samoa	Investment activities	16,349	16,349	500	100.00 %	264,979	777	777	Subsidiary
The Company	CHUNGTEX INVESTMENT CO., LTD.	Taipei	Investment activities	28,800	28,800	2,880	100.00 %	29,190	524	524	-
The Company	BIOTEQUE MEDICAL PHIL. INC.	Philippines	Manufacturing and Trading of Medical equipment	299,315	299,315	4,481	100.00 %	315,321	18,366	18,366	-
BIOTEQUE MEDICAL PHIL. INC.	BONTEO MEDICAL DISTRIBUTION PHIL. INC.	Philippines	Trading of Medical equipment	6,801	6,801	100	100.00 %	9,227	2,108	2,108	Investment through subsidiary

Note: The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

(c) Information on investment in Mainland China: None.

(Continued)



**BIOTEQUE CORPORATION AND SUBSIDIARIES**  
**Notes to the Consolidated Financial Statements**

**(14) Segment information:**

There were no significant changes in the Group's division, as well as the profit and loss measurement basis, as disclosed in the consolidated financial statements for the year December 31, 2018.

The Group's operating segment information and reconciliation were as follows:

	Three months ended March 31, 2019					Total
	Segment A	Segment B	Segment C	Other Segment	Reconciliation and elimination	
Revenue:						
Revenue from external customers	188,232	82,093	167,458	2,931	-	440,714
Intersegment revenue	-	5,563	-	-	(5,563)	-
Total revenue	<u>\$ 188,232</u>	<u>87,656</u>	<u>167,458</u>	<u>2,931</u>	<u>(5,563)</u>	<u>440,714</u>
Reporting segment profit or loss	<u>\$ 34,934</u>	<u>21,310</u>	<u>80,151</u>	<u>7,407</u>	<u>-</u>	<u>143,802</u>
	Three months ended March 31, 2018					Total
	Segment A	Segment B	Segment C	Other Segment	Reconciliation and elimination	
Revenue:						
Revenue from external customers	156,820	68,241	148,051	2,796	-	375,908
Intersegment revenue	-	4,876	-	-	(4,876)	-
Total revenue	<u>\$ 156,820</u>	<u>73,117</u>	<u>148,051</u>	<u>2,796</u>	<u>(4,876)</u>	<u>375,908</u>
Reporting segment profit or loss	<u>\$ 26,308</u>	<u>15,707</u>	<u>72,248</u>	<u>(8,769)</u>	<u>-</u>	<u>105,494</u>

The material reconciling items of the above reportable segment as below:

Total reportable segment revenue after deducting the intersegment revenue was \$5,563 and \$4,876 thousand dollars in the three months ended March 31, 2019 and 2018.